Publications by authors named "Jessica L Sheehan"
Article Synopsis
- Social determinants of health (SDOH) significantly affect vaccination disparities, especially among patients with inflammatory bowel disease (IBD), who are at greater infection risk.
- A study used census tract-level data from the CDC to assess the impact of SDOH on vaccination rates for flu, COVID-19, pneumonia, and herpes zoster in a cohort of 7,036 IBD patients.
- Results indicated that higher social vulnerability correlated with lower vaccination rates, highlighting the need to address these disparities to improve healthcare equity for IBD patients.
Article Synopsis
- The study examines how patient activation and self-efficacy impact the daily lives of individuals with inflammatory bowel disease (IBD).
- Researchers surveyed 132 IBD patients using various assessment tools and found that both higher patient activation and self-efficacy correlate with a lower burden of IBD.
- The results suggest that self-efficacy plays a significant role in mediating the relationship between patient activation and the effects of IBD on patients' daily lives.
Introduction: Depression and anxiety are highly prevalent among individuals with inflammatory bowel disease (IBD); however, little is understood about how social determinants of health (SDOH) may impact mental health diagnoses in this population. The social vulnerability index (SVI) is a publicly available tool that can be used to study SDOH in IBD patients.
Methods: Home addresses from a retrospective cohort of IBD patients at a single center were used to geocode patients to their individual census tract and corresponding SVI.
Introduction: Self-efficacy, i.e., the confidence in one's capacity to perform a behavior, is crucial to the development of inflammatory bowel disease (IBD) self-management skills.
View Article and Find Full Text PDFBackground: Dual targeted therapy (DTT) has emerged as an attractive therapeutic option for select patients with active inflammatory bowel disease (IBD) who are unable to achieve remission with biologic or small molecule monotherapy. We conducted a systematic review of specific DTT combinations in patients with IBD.
Methods: We conducted a systematic search of MEDLINE, EMBASE, Scopus, CINAHL Complete, Web of Science Core Collection, and Cochrane Library to identify articles related to the use of DTT for the treatment of Crohn Disease (CD) or ulcerative colitis (UC) published before February 2021.
Background: Pain is commonly experienced by patients with inflammatory bowel disease (IBD). Unfortunately, pain management is a challenge in IBD care, as currently available analgesics are associated with adverse events. Our understanding of the impact of opioid use on healthcare utilization among IBD patients remains limited.
View Article and Find Full Text PDFBackground & Aims: Despite rescue therapy, more than 30% of patients with acute severe ulcerative colitis (ASUC) require colectomy. Tofacitinib is a rapidly acting Janus kinase inhibitor with proven efficacy in ulcerative colitis. Tofacitinib may provide additional means for preventing colectomy in patients with ASUC.
View Article and Find Full Text PDF